{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:45:04Z","timestamp":1770511504323,"version":"3.49.0"},"reference-count":297,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"iMed.UL \u2014 Research Institute for Medicines and Pharmaceutical Sciences"},{"name":"Faculty of Pharmacy of the University of Lisbon, Portugal"},{"name":"Louvain Drug Research Institute"},{"name":"Universit\u00e9 Catholique de Louvain, Brussels, Belgium"},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, Minist\u00e9rio da Ci\u00eancia e Tecnologia, Portugal","award":["SFRH\/BD\/64295\/2009"],"award-info":[{"award-number":["SFRH\/BD\/64295\/2009"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, Minist\u00e9rio da Ci\u00eancia e Tecnologia, Portugal","award":["PTDC\/SAU-FAR\/119389\/2010"],"award-info":[{"award-number":["PTDC\/SAU-FAR\/119389\/2010"]}]},{"name":"Fonds de la Recherche Scientifique M\u00e9dicale (Belgium)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.jconrel.2013.03.010","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T00:16:07Z","timestamp":1363824967000},"page":"179-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":205,"title":["Immune system targeting by biodegradable nanoparticles for cancer vaccines"],"prefix":"10.1016","volume":"168","author":[{"given":"Joana M.","family":"Silva","sequence":"first","affiliation":[]},{"given":"Mafalda","family":"Videira","sequence":"additional","affiliation":[]},{"given":"Rog\u00e9rio","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"V\u00e9ronique","family":"Pr\u00e9at","sequence":"additional","affiliation":[]},{"given":"Helena F.","family":"Florindo","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jconrel.2013.03.010_bb0005","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-07-4804","article-title":"Targeted therapies to improve tumor immunotherapy","volume":"14","author":"Begley","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0010","first-page":"371","article-title":"Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear","volume":"84","author":"Dimberu","year":"2011","journal-title":"Yale J. Biol. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.smim.2010.03.004","article-title":"Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity","volume":"22","author":"Speiser","year":"2010","journal-title":"Semin. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0020","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/1521-4141(200107)31:7<2007::AID-IMMU2007>3.0.CO;2-S","article-title":"Comprehensive analysis of the frequency of recognition of melanoma associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy","volume":"31","author":"Benlalam","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2013.03.010_bb0025","first-page":"S63","article-title":"Regression in skin tumours: a common phenomenon","volume":"38","author":"Barnetson","year":"1997","journal-title":"Australas. J. Dermatol."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1309\/AJCPTXMEFOVYWDA6","article-title":"Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials","volume":"133","author":"Rao","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/106689690301100103","article-title":"Immunohistochemical markers of melanocytic tumors","volume":"11","author":"Yaziji","year":"2003","journal-title":"Int. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/imt.11.45","article-title":"Immunomodulatory cytokines as therapeutic agents for melanoma","volume":"3","author":"Nicholas","year":"2011","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcb.21473","article-title":"Melanoma cancer vaccines and anti-tumor T cell responses","volume":"102","author":"Vujanovic","year":"2007","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0050","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol. Pharm."},{"issue":"13","key":"10.1016\/j.jconrel.2013.03.010_bb0055","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.vaccine.2008.01.030","article-title":"TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses","volume":"26","author":"Schlosser","year":"2008","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.jconrel.2013.03.010_bb0060","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.vaccine.2005.01.082","article-title":"Cancer vaccines and immunotherapies: emerging perspectives","volume":"23","author":"Henderson","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0065","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication","volume":"8","author":"Verardi","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1529-8019.2009.01224.x","article-title":"Existing antiviral vaccines","volume":"22","author":"Ravanfar","year":"2009","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0075","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"10.1016\/j.jconrel.2013.03.010_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-1339-5","article-title":"History of Vaccine Development","author":"Plotkin","year":"2011"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nm0303-269","article-title":"Immunotherapy: past, present and future","volume":"9","author":"Waldmann","year":"2003","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0090","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1289\/ehp.0800439","article-title":"Endotoxin and cancer","volume":"117","author":"Lundin","year":"2009","journal-title":"Environ. Health Perspect."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0095","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4161\/onci.22428","article-title":"Trial watch: peptide vaccines in cancer therapy","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.addr.2008.12.009","article-title":"Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles","volume":"61","author":"Malyala","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","article-title":"Nanoparticle delivery systems in cancer vaccines","volume":"28","author":"Krishnamachari","year":"2011","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ctrv.2009.11.002","article-title":"The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer","volume":"36","author":"Matera","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0115","first-page":"2617","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"178","author":"Van der Bruggen","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","article-title":"A listing of human tumor antigens recognized by T cells: March 2004 update","volume":"54","author":"Novellino","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0125","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1586\/14760584.7.10.1547","article-title":"Overview of mimotopes and related strategies in tumor vaccine development","volume":"7","author":"Zhao","year":"2008","journal-title":"Expert Rev. Vaccines"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/94.11.805","article-title":"Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?","volume":"94","author":"Parmiani","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.jconrel.2013.03.010_bb0135","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4161\/cbt.8.15.9133","article-title":"Enhancing immune responses to tumor-associated antigens","volume":"8","author":"Higgins","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0140","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00262-010-0895-0","article-title":"Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles","volume":"59","author":"Pejawar-Gaddy","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.med.58.062105.204854","article-title":"Cancer stem cells: models and concepts","volume":"58","author":"Dalerba","year":"2007","journal-title":"Annu. Rev. Med."},{"issue":"20","key":"10.1016\/j.jconrel.2013.03.010_bb0150","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1158\/1078-0432.CCR-07-0686","article-title":"The universal character of the tumor-associated antigen survivin","volume":"13","author":"Andersen","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0155","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1349-7006.2012.02410.x","article-title":"Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT)","volume":"103","author":"Liao","year":"2012","journal-title":"Cancer Sci."},{"issue":"19","key":"10.1016\/j.jconrel.2013.03.010_bb0160","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/1078-0432.CCR-07-0879","article-title":"Universal and stemness-related tumor antigens: potential use in cancer immunotherapy","volume":"13","author":"Parmiani","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.190.5.651","volume":"190","author":"Anichini","year":"1999","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0170","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/sj.bjc.6600548","article-title":"Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients","volume":"87","author":"Maeda","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1490","article-title":"Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine","author":"Noguchi","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"17","key":"10.1016\/j.jconrel.2013.03.010_bb0180","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-05-2682","article-title":"Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy","volume":"12","author":"Sensi","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0185","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1349-7006.2006.00272.x","article-title":"Personalized peptide vaccines: a new therapeutic modality for cancer","volume":"97","author":"Itoh","year":"2006","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb0190","doi-asserted-by":"crossref","first-page":"e1002344","DOI":"10.1371\/journal.ppat.1002344","article-title":"Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery?","volume":"7","author":"Poland","year":"2011","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0195","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0205","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune resistance orchestrated by the tumor microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb0210","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2014revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb0215","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/eji.201242606","article-title":"Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies","volume":"42","author":"Aleksic","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1500","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1172\/JCI65325","article-title":"SHP-1 phosphatase activity counteracts increased T cell receptor affinity","volume":"123","author":"Hebeisen","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0225","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2004.10.041","article-title":"Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance","volume":"22","author":"Mapara","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0230","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clindermatol.2008.09.019","article-title":"Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma","volume":"27","author":"Ray","year":"2009","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0235","doi-asserted-by":"crossref","first-page":"741741","DOI":"10.1155\/2012\/741741","article-title":"Tumor-induced CD8+ T-cell dysfunction in lung cancer patients","volume":"2012","author":"Prado-Garcia","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0240","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.4049\/jimmunol.173.10.6017","article-title":"Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy","volume":"173","author":"Mehrotra","year":"2004","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb0245","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1505","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds647","article-title":"Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer","author":"Zielinski","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0260","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/imt.12.116","article-title":"Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity","volume":"4","author":"Morita","year":"2012","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0265","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00262-011-1171-7","article-title":"Disarming suppressor cells to improve immunotherapy","volume":"61","author":"Whiteside","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","article-title":"Multiple roles for CD4+ T cells in anti tumor immune responses","volume":"222","author":"Kennedy","year":"2008","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0275","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1073\/pnas.97.1.400","article-title":"Melan-A\/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells","volume":"97","author":"Zarour","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0280","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CJI.0b013e3182187600","article-title":"Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies","volume":"34","author":"Kerkar","year":"2011","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2567.2005.02268.x","article-title":"Enhanced and prolonged cross presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles","volume":"117","author":"Shen","year":"2006","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0290","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.semcancer.2012.03.003","article-title":"The role of classical and non-classical HLA class I antigens in human tumors","volume":"22","author":"Bukur","year":"2012","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0295","first-page":"487","article-title":"MHC class I down-regulation: tumour escape from immune surveillance? (Review)","volume":"25","author":"Buben\u00edk","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0300","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"issue":"41","key":"10.1016\/j.jconrel.2013.03.010_bb0305","doi-asserted-by":"crossref","first-page":"16618","DOI":"10.1073\/pnas.1117610109","article-title":"TGF-\u03b2 blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/ctrv.1998.0104","article-title":"Genetically modified tumour vaccines\u2014where we are today","volume":"25","author":"Nawrocki","year":"1999","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1510","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2013.01.042","article-title":"Microenvironment and tumor cell plasticity: an easy way out","author":"Taddei","year":"2013","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0320","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00005-007-0029-3","article-title":"Tumor resistance to CD8+ T cell-based therapeutic vaccination","volume":"55","author":"Huang","year":"2007","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0325","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2009-06-227546","article-title":"Memories that last forever: strategies for optimizing vaccine T-cell memory","volume":"115","author":"Ahlers","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0330","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1084\/jem.190.5.617","article-title":"Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo","volume":"190","author":"Nishimura","year":"1999","journal-title":"J. Exp. Med."},{"issue":"2A","key":"10.1016\/j.jconrel.2013.03.010_bb0335","first-page":"1113","article-title":"Molecular immunological approaches to biotherapy of human cancers\u2014a review, hypothesis and implications","volume":"26","author":"Becker","year":"2006","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0340","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1359","article-title":"The promise of cancer vaccines","volume":"4","author":"Gilboa","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0345","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4049\/jimmunol.175.3.1373","article-title":"Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity","volume":"175","author":"Rossi","year":"2005","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.jconrel.2013.03.010_bb0350","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2008-12-180646","article-title":"Dendritic cell homeostasis","volume":"113","author":"Merad","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0355","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb0360","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00262-012-1305-6","article-title":"Innate immune sensing of cancer: clues from an identified role for type I IFNs","volume":"61","author":"Gajewski","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"5715","key":"10.1016\/j.jconrel.2013.03.010_bb0365","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1108003","article-title":"Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate","volume":"307","author":"Delamarre","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2332\/allergolint.R-07-146","article-title":"Dendritic cells: a conductor of T cell differentiation","volume":"56","author":"Kadowaki","year":"2007","journal-title":"Allergol. Int."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0375","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20030448","article-title":"Regulation of dendritic cell migration to the draining lymph node","volume":"198","author":"Mart\u00edn-Fontecha","year":"2003","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0380","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/CJI.0b013e31818403bc","article-title":"Dendritic cells: a critical player in cancer therapy?","volume":"31","author":"Palucka","year":"2008","journal-title":"J. Immunother."},{"issue":"17","key":"10.1016\/j.jconrel.2013.03.010_bb0385","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers' entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"7272","key":"10.1016\/j.jconrel.2013.03.010_bb0390","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature08604","article-title":"Materials engineering for immunomodulation","volume":"462","author":"Hubbell","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0395","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.it.2008.06.004","article-title":"MHC class I assembly: out and about","volume":"29","author":"Raghavan","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0400","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2741\/3695","article-title":"Receptor-mediated T cell absorption of antigen presenting cell-derived molecules","volume":"16","author":"Hwang","year":"2011","journal-title":"Front. Biosci."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0405","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2332\/allergolint.R-07-149","article-title":"Dendritic cells: ontogeny","volume":"56","author":"Takeuchi","year":"2007","journal-title":"Allergol. Int."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.coi.2009.02.004","article-title":"Adoptive immunotherapy of cancer using CD4+ T cells","volume":"21","author":"Muranski","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0415","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/eji.200425889","article-title":"Coming of age: carbohydrates and immunity","volume":"35","author":"Cobb","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0420","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.plipres.2009.10.002","article-title":"How the immune system detects lipid antigens","volume":"49","author":"De Libero","year":"2010","journal-title":"Prog. Lipid Res."},{"issue":"34","key":"10.1016\/j.jconrel.2013.03.010_bb0425","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.1108809108","article-title":"Fine tuning by human CD1e of lipid-specific immune responses","volume":"108","author":"Facciotti","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0430","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/eji.200939425","article-title":"The cellular and biochemical rules of lipid antigen presentation","volume":"39","author":"De Libero","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.smim.2009.10.004","article-title":"Antigen recognition by CD1d-restricted NKT T cell receptors","volume":"22","author":"Godfrey","year":"2010","journal-title":"Semin. Immunol."},{"issue":"28","key":"10.1016\/j.jconrel.2013.03.010_bb0440","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.2174\/138161209789105108","article-title":"Presentation of lipid antigens by CD1 glycoproteins","volume":"15","author":"Schiefner","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0445","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J. Exp. Med."},{"issue":"23","key":"10.1016\/j.jconrel.2013.03.010_bb0450","first-page":"5309","article-title":"Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism","volume":"56","author":"Hakomori","year":"1996","journal-title":"Cancer Res."},{"issue":"48","key":"10.1016\/j.jconrel.2013.03.010_bb0455","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1016\/j.vaccine.2011.09.009","article-title":"Cancer vaccines and carbohydrate epitopes","volume":"29","author":"Heimburg-Molinaro","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2013.03.010_bb0460","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4161\/hv.7.0.14578","article-title":"Glycan mediated immune responses to tumor cells","volume":"7","author":"Pashov","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0465","first-page":"1045","article-title":"Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine","volume":"17","author":"Monzavi-Karbassi","year":"2006","journal-title":"Int. J. Mol. Med."},{"issue":"17","key":"10.1016\/j.jconrel.2013.03.010_bb0470","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0475","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-2776(04)82006-6","article-title":"MUC1 immunobiology: from discovery to clinical applications","volume":"82","author":"Vlad","year":"2004","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1515","doi-asserted-by":"crossref","DOI":"10.1039\/c3cs35470a","article-title":"The development of synthetic antitumour vaccines from mucin glycopeptide antigens","author":"Gaidzik","year":"2013","journal-title":"Chem. Soc. Rev."},{"issue":"41","key":"10.1016\/j.jconrel.2013.03.010_bb0485","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/anie.200902564","article-title":"A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response","volume":"48","author":"Kaiser","year":"2009","journal-title":"Angew. Chem. Int. Ed Engl."},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0490","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/anie.201106396","article-title":"Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response","volume":"51","author":"Cai","year":"2012","journal-title":"Angew. Chem. Int. Ed Engl."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb0495","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00262-008-0503-8","article-title":"Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge","volume":"57","author":"Mazorra","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20090272","article-title":"Pathogen recognition in the innate immune response","volume":"420","author":"Kumar","year":"2009","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0505","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-065X.2008.00733.x","article-title":"Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases","volume":"227","author":"Beutler","year":"2009","journal-title":"Immunol. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2013.03.010_bb0510","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00018-011-0699-1","article-title":"Modulation of \u03b3\u03b4 T cell responses by TLR ligands","volume":"68","author":"Wesch","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0515","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00262-010-0833-1","article-title":"Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy","volume":"59","author":"Schreibelt","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0520","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-71029-5_1","article-title":"Activation of dendritic cells by Toll-like receptors and C-type lectins","volume":"188","author":"Diebold","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0525","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0530","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1084\/jem.20041964","article-title":"A type I interferon autocrine\u2013paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells","volume":"201","author":"Gautier","year":"2005","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0535","doi-asserted-by":"crossref","first-page":"e19323","DOI":"10.1371\/journal.pone.0019323","article-title":"Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7\/8 agonists in macaques","volume":"6","author":"Sariol","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0540","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0545","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2249.2010.04091.x","article-title":"Modulation of immune responses through direct activation of Toll like receptors to T cells","volume":"160","author":"Liu","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0550","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.4049\/jimmunol.0901941","article-title":"Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides","volume":"183","author":"Avalos","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1520","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0560","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1042\/BST0351461","article-title":"Synthetic agonists of Toll-like receptors 7, 8 and 9","volume":"35","author":"Agrawal","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"33","key":"10.1016\/j.jconrel.2013.03.010_bb0565","doi-asserted-by":"crossref","first-page":"8702","DOI":"10.1016\/j.biomaterials.2011.07.085","article-title":"Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex","volume":"32","author":"Barata","year":"2011","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0570","doi-asserted-by":"crossref","first-page":"e1002095","DOI":"10.1371\/journal.pcbi.1002095","article-title":"Partially glycosylated dendrimers block MD-2 and prevent TLR4\u2013MD-2\u2013LPS complex mediated cytokine responses","volume":"7","author":"Barata","year":"2011","journal-title":"PLoS Comput. Biol."},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0575","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/eji.201142361","article-title":"Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients","volume":"42","author":"Goldinger","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0580","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","article-title":"Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma","volume":"29","author":"Link","year":"2006","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0585","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1215\/S1522851705000475","article-title":"Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma","volume":"8","author":"Carpentier","year":"2006","journal-title":"Neuro Oncol."},{"issue":"24","key":"10.1016\/j.jconrel.2013.03.010_bb0590","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2007.12.5807","article-title":"Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer","volume":"26","author":"Manegold","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1525","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ecp.11.5","article-title":"The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system","volume":"4","author":"Engel","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.imlet.2009.10.005","article-title":"The ABC of clinical and experimental adjuvants\u2014a brief overview","volume":"128","author":"Brunner","year":"2010","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0605","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol. Cell Biol."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0610","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.171.10.5140","article-title":"NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells","volume":"171","author":"Hermans","year":"2003","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0615","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00262-005-0048-z","article-title":"Role of immature myeloid cells in mechanisms of immune evasion in cancer","volume":"55","author":"Kusmartsev","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"issue":"18","key":"10.1016\/j.jconrel.2013.03.010_bb0620","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0625","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.4049\/jimmunol.1002320","article-title":"TLR1\/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells","volume":"186","author":"Zhang","year":"2011","journal-title":"J. Immunol."},{"issue":"6\u20137","key":"10.1016\/j.jconrel.2013.03.010_bb0630","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejcb.2010.11.012","article-title":"Regulation of T cell activation by TLR ligands","volume":"90","author":"Oberg","year":"2011","journal-title":"Eur. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0635","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2005-10-4015","article-title":"Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo","volume":"108","author":"Warger","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0640","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ni1059","article-title":"Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance","volume":"5","author":"Yang","year":"2004","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0645","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1084\/jem.20021633","article-title":"Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide","volume":"197","author":"Caramalho","year":"2003","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0650","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.4049\/jimmunol.0901465","article-title":"Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival","volume":"183","author":"Chen","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb0655","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/eji.201041387","article-title":"The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells","volume":"41","author":"Olivier","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1530","article-title":"Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance","author":"Tanchot","year":"2012","journal-title":"Cancer Microenviron."},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0665","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1078-0432.CCR-10-2672","article-title":"CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice","volume":"17","author":"Zoglmeier","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0670","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.0105-2896.2010.00899.x","article-title":"Plasticity in programming of effector and memory CD8+ T cell formation","volume":"235","author":"Arens","year":"2010","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0675","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"23","key":"10.1016\/j.jconrel.2013.03.010_bb0680","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.vaccine.2009.03.034","article-title":"Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy","volume":"27","author":"Demento","year":"2009","journal-title":"Vaccine"},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2013.03.010_bb0685","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0168-3659(02)00275-4","article-title":"Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres","volume":"85","author":"Diwan","year":"2002","journal-title":"J. Control. Release"},{"issue":"28","key":"10.1016\/j.jconrel.2013.03.010_bb0690","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1016\/j.biomaterials.2009.05.045","article-title":"Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres","volume":"30","author":"Florindo","year":"2009","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0695","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nano.2010.03.001","article-title":"Delivery of a peptide via poly (d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity","volume":"6","author":"Clawson","year":"2010","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0700","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijpharm.2011.04.068","article-title":"Activation of invariant Natural Killer T lymphocytes in response to the \u03b1-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles","volume":"423","author":"Macho Fernandez","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0705","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.03.010_bb0710","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuroscience.2011.11.013","article-title":"Fever, sickness behavior, and expression of inflammatory genes in the hypothalamus after systemic and localized subcutaneous stimulation of rats with the Toll-like receptor 7 agonist imiquimod","volume":"201","author":"Damm","year":"2012","journal-title":"Neuroscience"},{"issue":"26","key":"10.1016\/j.jconrel.2013.03.010_bb0715","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1182\/blood-2011-07-367615","article-title":"Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity","volume":"118","author":"Tacken","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jconrel.2013.03.010_bb0720","doi-asserted-by":"crossref","first-page":"E797","DOI":"10.1073\/pnas.1121423109","article-title":"Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery","volume":"109","author":"Nguyen","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0725","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0939-6411(00)00062-X","article-title":"Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables","volume":"50","author":"Jain","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb0730","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.it.2006.06.005","article-title":"Toll-like receptors on regulatory T cells: expanding immune regulation","volume":"27","author":"Sutmuller","year":"2006","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0735","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jconrel.2011.04.014","article-title":"Mechanism of cross-presentation of microencapsulated antigen","volume":"151","author":"Park","year":"2011","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0740","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1096\/fj.02-0088com","article-title":"Rapid endo-lysosomal escape of poly (dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery","volume":"16","author":"Panyam","year":"2002","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0745","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.0818-9641.2004.01271.x","article-title":"Vaccines that facilitate antigen entry into dendritic cells","volume":"82","author":"Gamvrellis","year":"2004","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0750","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.addr.2008.12.013","article-title":"Innovative strategies for co-delivering antigens and CpG oligonucleotides","volume":"61","author":"Krishnamachari","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"39","key":"10.1016\/j.jconrel.2013.03.010_bb0755","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1016\/j.vaccine.2008.07.035","article-title":"Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity","volume":"26","author":"Hamdy","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb0760","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s12272-010-1119-z","article-title":"Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen","volume":"33","author":"Lee","year":"2010","journal-title":"Arch. Pharm. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0765","doi-asserted-by":"crossref","first-page":"e7334","DOI":"10.1371\/journal.pone.0007334","article-title":"Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-like receptor agonists as a treatment for melanoma","volume":"4","author":"Stone","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0770","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2010.06.009","article-title":"Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination","volume":"148","author":"Sl\u00fctter","year":"2010","journal-title":"J. Control. Release"},{"issue":"7335","key":"10.1016\/j.jconrel.2013.03.010_bb0775","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.jconrel.2013.03.010_bb0780","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.molimm.2009.05.011","article-title":"Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3","volume":"46","author":"Tross","year":"2009","journal-title":"Mol. Immunol."},{"issue":"1-2","key":"10.1016\/j.jconrel.2013.03.010_bb1535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2005.10.046","article-title":"Development of new polymer-based particulate systems for anti-glioma vaccination","volume":"309","author":"Sapin","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0790","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","article-title":"Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model","volume":"298","author":"Foged","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0795","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: does size matter?","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0805","doi-asserted-by":"crossref","first-page":"e1000394","DOI":"10.1371\/journal.ppat.1000394","article-title":"Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization","volume":"5","author":"Cureton","year":"2009","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb1540","doi-asserted-by":"crossref","first-page":"e1001127","DOI":"10.1371\/journal.ppat.1001127","article-title":"The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis","volume":"6","author":"Cureton","year":"2010","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0815","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11671-007-9081-5","article-title":"Nanoparticles for applications in cellular imaging","volume":"2","author":"Thurn","year":"2007","journal-title":"Nanoscale Res. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0820","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2009.12.022","article-title":"Endocytic uptake of a large array of HPMA copolymers: elucidation into the dependence on the physicochemical characteristics","volume":"143","author":"Liu","year":"2010","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb1545","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1021\/bm101482r","article-title":"Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles","volume":"12","author":"Yue","year":"2011","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0830","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/ar200113c","article-title":"Nanoparticle \u03b6-potentials","volume":"45","author":"Doane","year":"2012","journal-title":"Acc. Chem. Res."},{"issue":"14\u201315","key":"10.1016\/j.jconrel.2013.03.010_bb1550","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.addr.2011.06.016","article-title":"The effects of polymeric nanostructure shape on drug delivery","volume":"63","author":"Venkataraman","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2013.03.010_bb0840","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/smll.201102002","article-title":"How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells","volume":"8","author":"Florez","year":"2012","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0845","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1555","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cis.2007.04.021","article-title":"The nanoparticle\u2013protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century","volume":"134-135","author":"Lynch","year":"2007","journal-title":"Adv. Colloid Interface Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0855","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0860","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"issue":"38","key":"10.1016\/j.jconrel.2013.03.010_bb0865","doi-asserted-by":"crossref","first-page":"14265","DOI":"10.1073\/pnas.0805135105","article-title":"Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts","volume":"105","author":"Lundqvist","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb0870","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1021\/nn201950e","article-title":"Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis","volume":"5","author":"Tenzer","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2013.03.010_bb0875","doi-asserted-by":"crossref","first-page":"727241","DOI":"10.1155\/2011\/727241","article-title":"Targeted liposomal drug delivery to monocytes and macrophages","volume":"2011","author":"Kelly","year":"2011","journal-title":"J. Drug Deliv."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb0880","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.nano.2008.05.006","article-title":"Novel nanoparticles for the delivery of recombinant hepatitis B vaccine","volume":"4","author":"Bharali","year":"2008","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0885","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1021\/bm201690w","article-title":"Synthesis of poly(lactide-co-glycolide-co-\u03b5-caprolactone)-graft-mannosylated poly(ethylene oxide) copolymers by combination of \u00abclip\u00bb and \u00abclick\u00bb chemistries","volume":"13","author":"Freichels","year":"2012","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0890","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jconrel.2009.09.005","article-title":"Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity","volume":"141","author":"Van den Berg","year":"2010","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0895","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/bm060889x","article-title":"Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG","volume":"8","author":"Fernandez-Megia","year":"2007","journal-title":"Biomacromolecules"},{"issue":"Pt 6","key":"10.1016\/j.jconrel.2013.03.010_bb0900","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1042\/BST0361478","article-title":"C-type lectins on dendritic cells: key modulators for the induction of immune responses","volume":"36","author":"Van Kooyk","year":"2008","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0905","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coi.2010.11.011","article-title":"\u00abDressed for success\u00bb C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells","volume":"23","author":"Unger","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb0910","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.imbio.2008.11.004","article-title":"Influence of the mannose receptor in host immune responses","volume":"214","author":"Gazi","year":"2009","journal-title":"Immunobiology"},{"issue":"5824","key":"10.1016\/j.jconrel.2013.03.010_bb0915","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1137971","article-title":"Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation","volume":"316","author":"Burgdorf","year":"2007","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb1560","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s11095-011-0459-9","article-title":"Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles","volume":"28","author":"Hamdy","year":"2011","journal-title":"Pharm. Res."},{"issue":"4\u20135","key":"10.1016\/j.jconrel.2013.03.010_bb0925","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejps.2008.11.013","article-title":"Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages","volume":"36","author":"Brandhonneur","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0930","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/1061186X.2010.492522","article-title":"Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis","volume":"19","author":"Saraogi","year":"2011","journal-title":"J. Drug Target."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb0935","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1021\/bc8002524","article-title":"Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes","volume":"19","author":"Espuelas","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb0940","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.4049\/jimmunol.178.10.6259","article-title":"Antigenic targeting of the human mannose receptor induces tumor immunity","volume":"178","author":"He","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb0945","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.4049\/jimmunol.172.5.2845","article-title":"Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules","volume":"172","author":"Ramakrishna","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb0950","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/jid.2009.343","article-title":"Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis","volume":"130","author":"Flacher","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0955","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb0960","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0142-9612(96)85754-1","article-title":"Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid\/polyglycolic acid copolymers","volume":"17","author":"Athanasiou","year":"1996","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb0965","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1021\/bm034247a","article-title":"Recent developments in ring opening polymerization of lactones for biomedical applications","volume":"4","author":"Albertsson","year":"2003","journal-title":"Biomacromolecules"},{"issue":"22","key":"10.1016\/j.jconrel.2013.03.010_bb0970","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0142-9612(97)00076-8","article-title":"Synthesis of polylactides with different molecular weights","volume":"18","author":"Hyon","year":"1997","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0975","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1039\/B810065A","article-title":"Stereocontrolled ring-opening polymerization of cyclic esters: synthesis of new polyester microstructures","volume":"39","author":"Thomas","year":"2010","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb0980","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1021\/cr990121l","article-title":"Enzymatic polymerization","volume":"101","author":"Kobayashi","year":"2001","journal-title":"Chem. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb0985","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0167-7799(92)90246-R","article-title":"Enzymatic and chemoenzymatic approaches to polymer synthesis","volume":"10","author":"Dordick","year":"1992","journal-title":"Trends Biotechnol."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb0990","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1021\/cr040002s","article-title":"Controlled ring-opening polymerization of lactide and glycolide","volume":"104","author":"Dechy-Cabaret","year":"2004","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb0995","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15583720701834166","article-title":"Biocompatible initiators for lactide polymerization","volume":"48","author":"Platel","year":"2008","journal-title":"Polym. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1000","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0045-6535(00)00323-4","article-title":"Syntheses and application of polylactides","volume":"43","author":"Kricheldorf","year":"2001","journal-title":"Chemosphere"},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb1005","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1039\/b820162p","article-title":"Synthesis of polycaprolactone: a review","volume":"38","author":"Labet","year":"2009","journal-title":"Chem. Soc. Rev."},{"issue":"17","key":"10.1016\/j.jconrel.2013.03.010_bb1010","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/0142-9612(95)91044-Y","article-title":"Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins","volume":"16","author":"Huatan","year":"1995","journal-title":"Biomaterials"},{"issue":"1-3","key":"10.1016\/j.jconrel.2013.03.010_bb1015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0141-8130(99)00033-1","article-title":"Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers","volume":"25","author":"Abe","year":"1999","journal-title":"Int. J. Biol. Macromol."},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb1020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1163\/156856297X00074","article-title":"Characterization of partially saturated poly(propylene fumarate) for orthopaedic application","volume":"8","author":"Peter","year":"1997","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00289-010-0268-z","article-title":"Synthesis of poly(ethylene adipate-co-l-lactic acid) copolymers via ring opening polymerization","volume":"66","author":"Liu","year":"2011","journal-title":"Polym. Bull."},{"issue":"18","key":"10.1016\/j.jconrel.2013.03.010_bb1030","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/ma201169z","article-title":"A strategy for control of \u00abrandom\u00bb copolymerization of lactide and glycolide: application to synthesis of PEG-b-PLGA block polymers having narrow dispersity","volume":"44","author":"Qian","year":"2011","journal-title":"Macromolecules"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-3057(98)80001-3","article-title":"Copolymerization of \u03b3-valerolactone and \u03b2-butyrolactone","volume":"34","author":"Lee","year":"1998","journal-title":"Eur. Polym. J."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb1040","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1021\/bm2004675","article-title":"Macromolecular design of aliphatic polyesters with maintained mechanical properties and a rapid, customized degradation profile","volume":"12","author":"Malberg","year":"2011","journal-title":"Biomacromolecules"},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb1045","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.progpolymsci.2010.04.002","article-title":"The return of a forgotten polymer\u2014polycaprolactone in the 21st century","volume":"35","author":"Woodruff","year":"2010","journal-title":"Prog. Polym. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/bm015658z","article-title":"Resorbable and highly elastic block copolymers from 1,5-dioxepan-2-one and l-lactide with controlled tensile properties and hydrophilicity","volume":"3","author":"Ryner","year":"2002","journal-title":"Biomacromolecules"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb1055","first-page":"1125","article-title":"Polylactic acid (PLA): research, development and industrialization","volume":"5","author":"Pang","year":"2010","journal-title":"Biotechnology"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb1060","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0142-9612(02)00613-0","article-title":"Macroporous poly(3-hydroxybutyrate-co-3-hydroxyvalerate) matrices for bone tissue engineering","volume":"24","author":"K\u00f6se","year":"2003","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb1065","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.actbio.2009.03.017","article-title":"The fabrication and characterization of biodegradable HA\/PHBV nanoparticle\u2013polymer composite scaffolds","volume":"5","author":"Jack","year":"2009","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1070","first-page":"89","article-title":"Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres for the sustained release of 5-fluorouracil","volume":"11","author":"Khang","year":"2001","journal-title":"Biomed. Mater. Eng."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1075","doi-asserted-by":"crossref","first-page":"542937","DOI":"10.1100\/2012\/542937","article-title":"PHBV\/PCL microparticles for controlled release of resveratrol: physicochemical characterization, antioxidant potential, and effect on hemolysis of human erythrocytes","volume":"2012","author":"Mendes","year":"2012","journal-title":"Scientific World Journal"},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb1080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/erm.09.15","article-title":"Current advances in research and clinical applications of PLGA-based nanotechnology","volume":"9","author":"L\u00fc","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"23","key":"10.1016\/j.jconrel.2013.03.010_bb1085","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/S0142-9612(00)00115-0","article-title":"The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices","volume":"21","author":"Jain","year":"2000","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb1090","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11095-010-0077-y","article-title":"Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration","volume":"27","author":"Soderquist","year":"2010","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2010.11.008","article-title":"High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization","volume":"77","author":"Cun","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/mp060107e","article-title":"Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells","volume":"4","author":"Solbrig","year":"2007","journal-title":"Mol. Pharm."},{"issue":"8\u201310","key":"10.1016\/j.jconrel.2013.03.010_bb1105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10611860410001670026","article-title":"Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses","volume":"11","author":"Diwan","year":"2003","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2010.07.002","article-title":"Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy","volume":"7","author":"Prasad","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1115","first-page":"905","article-title":"Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine","volume":"27","author":"Thomas","year":"2010","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.fsi.2010.09.016","article-title":"Cell biology of antigen processing in vitro and in vivo","volume":"30","author":"Tian","year":"2010","journal-title":"Fish Shellfish Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2004.09.003","article-title":"Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens","volume":"57","author":"Jiang","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jconrel.2007.04.021","article-title":"PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination","volume":"120","author":"Garinot","year":"2007","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb1135","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.vaccine.2008.12.004","article-title":"New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model","volume":"27","author":"Florindo","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb1140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2174\/1567201043334597","article-title":"Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery","volume":"1","author":"Diwan","year":"2004","journal-title":"Curr. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.01.044","article-title":"Poly-[epsilon]-caprolactone microspheres and nanospheres: an overview","volume":"278","author":"Sinha","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"6080","key":"10.1016\/j.jconrel.2013.03.010_bb1150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1126\/science.1215368","article-title":"Multiblock polymers: panacea or Pandora's box?","volume":"336","author":"Bates","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-409X(01)00244-7","article-title":"ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins","volume":"54","author":"Kissel","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1160","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jconrel.2011.04.028","article-title":"Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery","volume":"155","author":"Xiong","year":"2011","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb1165","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10397","article-title":"Amphiphilic block copolymers for drug delivery","volume":"92","author":"Adams","year":"2003","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cimid.2010.02.003","article-title":"Immunogenicity of multiple-epitope antigen gene of HCV carried by novel biodegradable polymers","volume":"34","author":"Yang","year":"2011","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"issue":"17","key":"10.1016\/j.jconrel.2013.03.010_bb1175","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/marc.201000090","article-title":"Synthesis, characterization and preliminary biological evaluation of P(HPMA)-b-P(LLA) copolymers: a new type of functional biocompatible block copolymer","volume":"31","author":"Barz","year":"2010","journal-title":"Macromol. Rapid Commun."},{"issue":"33","key":"10.1016\/j.jconrel.2013.03.010_bb1180","doi-asserted-by":"crossref","first-page":"9983","DOI":"10.1021\/jp303402j","article-title":"Investigation of poly(lactide) stereocomplexes: 3-armed poly(l-lactide) blended with linear and 3-armed enantiomers","volume":"116","author":"Shao","year":"2012","journal-title":"J. Phys. Chem. B"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2012.05.024","article-title":"P(HPMA)-block-P(LA) copolymers in paclitaxel formulations: polylactide stereochemistry controls micellization, cellular uptake kinetics, intracellular localization and drug efficiency","volume":"163","author":"Barz","year":"2012","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/mp050103u","article-title":"Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation","volume":"3","author":"Ahmed","year":"2006","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.polymer.2008.09.049","article-title":"Core cross-linked star polymers via controlled radical polymerisation","volume":"50","author":"Blencowe","year":"2009","journal-title":"Polymer"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1200","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1039\/C0CS00091D","article-title":"Aliphatic polyester polymer stars: synthesis, properties and applications in biomedicine and nanotechnology","volume":"40","author":"Cameron","year":"2011","journal-title":"Chem. Soc. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb1205","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.actbio.2012.06.011","article-title":"Photo-crosslinked networks prepared from fumaric acid monoethyl ester-functionalized poly(d, l-lactic acid) oligomers and N-vinyl-2-pyrrolidone for the controlled and sustained release of proteins","volume":"8","author":"Jansen","year":"2012","journal-title":"Acta Biomater."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb1210","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s10856-009-3761-x","article-title":"Amorphous phase-segregated copoly(ether)esterurethane thermoset networks with oligo(propylene glycol) and oligo[(rac-lactide)-co-glycolide] segments: synthesis and characterization","volume":"20","author":"Zotzmann","year":"2009","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2013.03.010_bb1565","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1163\/092050610X521586","article-title":"Biodegradable nano-aggregates of star-shaped 8-arm PEG -PLLA block co-polymers for encapsulation of water-soluble macromolecules","volume":"22","author":"Nagahama","year":"2011","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb1220","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF00701240","article-title":"Bioresorbability and biocompatibility of aliphatic polyesters","volume":"3","author":"Vert","year":"1992","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb1570","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1243\/0954411041932782","article-title":"Degradation of poly-l-lactide. Part 1: in vitro and in vivo physiological temperature degradation","volume":"218","author":"Weir","year":"2004","journal-title":"Proc. Inst. Mech. Eng. H"},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb1230","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0169-409X(02)00051-0","article-title":"Polyanhydride degradation and erosion","volume":"54","author":"G\u00f6pferich","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1235","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/(SICI)1097-4636(1999)48:3<342::AID-JBM20>3.0.CO;2-7","article-title":"Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids","volume":"48","author":"Li","year":"1999","journal-title":"J. Biomed. Mater. Res."},{"issue":"16","key":"10.1016\/j.jconrel.2013.03.010_bb1240","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.biomaterials.2004.08.031","article-title":"Effect of isothermal annealing on the hydrolytic degradation rate of poly (lactide-co-glycolide)(PLGA)","volume":"26","author":"Loo","year":"2005","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2012.10.015","article-title":"Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres \u2014 a review","volume":"165","author":"Ford Versypt","year":"2013","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2013.03.010_bb1250","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/jps.21176","article-title":"Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms","volume":"97","author":"Houchin","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly (d, l-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1260","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.addr.2004.09.007","article-title":"PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines","volume":"57","author":"Waeckerle-Men","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1265","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpharm.2008.06.030","article-title":"Immunomodulatory biomaterials","volume":"364","author":"Mallapragada","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb1270","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/mabi.201200223","article-title":"Functionalized polystyrene nanoparticles trigger human dendritic cell maturation resulting in enhanced CD4+ T cell activation","volume":"12","author":"Frick","year":"2012","journal-title":"Macromol. Biosci."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb1275","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.intimp.2011.05.014","article-title":"The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response","volume":"11","author":"Nicolete","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb1280","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.biomaterials.2006.10.034","article-title":"The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles","volume":"28","author":"Fischer","year":"2007","journal-title":"Biomaterials"},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2013.03.010_bb1285","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.molimm.2006.06.020","article-title":"The role of complement in biomaterial-induced inflammation","volume":"44","author":"Nilsson","year":"2007","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb1290","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.addr.2011.06.002","article-title":"Material properties in complement activation","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"22","key":"10.1016\/j.jconrel.2013.03.010_bb1295","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/S0142-9612(01)00043-6","article-title":"Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules","volume":"22","author":"Mosqueira","year":"2001","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb1300","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3748\/wjg.v10.i5.660","article-title":"Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells","volume":"10","author":"He","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1305","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1166\/jbn.2011.1244","article-title":"Synthesis of biodegradable polymeric nanoparticles and their controlled drug delivery for tuberculosis","volume":"7","author":"Malathi","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2006.08.013","article-title":"Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach","volume":"116","author":"Des Rieux","year":"2006","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1315","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2008.02.007","article-title":"Design and production of nanoparticles formulated from nano-emulsion templates\u2014a review","volume":"128","author":"Anton","year":"2008","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2013.03.010_bb1320","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vetmic.2006.07.004","article-title":"Encapsulation of antigenic extracts of Salmonella enterica serovar: Abortusovis into polymeric systems and efficacy as vaccines in mice","volume":"118","author":"Estevan","year":"2006","journal-title":"Vet. Microbiol."},{"issue":"33","key":"10.1016\/j.jconrel.2013.03.010_bb1325","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1016\/j.vaccine.2008.05.074","article-title":"S. equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses","volume":"26","author":"Florindo","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","article-title":"Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake","volume":"82","author":"Sahoo","year":"2002","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1335","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.addr.2004.09.008","article-title":"Immunity in response to particulate antigen-delivery systems","volume":"57","author":"Storni","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"31","key":"10.1016\/j.jconrel.2013.03.010_bb1340","doi-asserted-by":"crossref","first-page":"23739","DOI":"10.1074\/jbc.M110.126359","article-title":"Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength","volume":"285","author":"Rajapaksa","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2013.03.010_bb1575","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/jbm.a.34040","article-title":"Effects of surfactants on the properties of PLGA nanoparticles","volume":"100A","author":"Menon","year":"2012","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb1350","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3109\/03639045.2011.650864","article-title":"Simultaneous quantification of polymeric and surface active stabilizers of nanosuspensions by using near-infrared spectroscopy","volume":"38","author":"Cerdeira","year":"2012","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb1580","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1208\/s12249-009-9330-2","article-title":"Surfactant-free formulation of poly(lactic\/glycolic) acid nanoparticles encapsulating functional polypeptide: a technical note","volume":"10","author":"Wang","year":"2009","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"10.1016\/j.jconrel.2013.03.010_bb1360","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2006.09.004","article-title":"T cell memory and protective immunity by vaccination: is more better?","volume":"27","author":"Zanetti","year":"2006","journal-title":"Trends Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2013.03.010_bb1365","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpharm.2006.05.007","article-title":"Uptake characteristics of NGR-coupled stealth PEI\/pDNA nanoparticles loaded with PLGA\u2013PEG\u2013PLGA tri-block copolymer for targeted delivery to human monocyte-derived dendritic cells","volume":"321","author":"Moffatt","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb1370","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10544-009-9336-2","article-title":"Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles","volume":"11","author":"Shan","year":"2009","journal-title":"Biomed. Microdevices"},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb1375","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/icb.2010.39","article-title":"Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy","volume":"88","author":"Romani","year":"2010","journal-title":"Immunol. Cell Biol."},{"issue":"5","key":"10.1016\/j.jconrel.2013.03.010_bb1380","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1189\/jlb.0807567","article-title":"Human Langerhans cells selectively activated via Toll-like receptor 2 agonists acquire migratory and CD4+ T cell stimulatory capacity","volume":"83","author":"Peiser","year":"2008","journal-title":"J. Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb1385","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.it.2010.08.006","article-title":"In vivo function of Langerhans cells and dermal dendritic cells","volume":"31","author":"Kaplan","year":"2010","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb1390","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2013.03.010_bb1395","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/jid.2009.176","article-title":"Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis","volume":"129","author":"Kim","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2332\/allergolint.R-06-139","article-title":"Dendritic cells: nature and classification","volume":"56","author":"Sato","year":"2007","journal-title":"Allergol. Int."},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1405","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1084\/jem.185.2.317","article-title":"Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures","volume":"185","author":"Winzler","year":"1997","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2013.03.010_bb1410","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/mt.2009.275","article-title":"Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma","volume":"18","author":"Adamina","year":"2009","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.jconrel.2013.03.010_bb1415","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1158\/1078-0432.CCR-09-0645","article-title":"Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors","volume":"15","author":"Smith","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2013.03.010_bb1420","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb1425","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1073\/pnas.051630798","article-title":"Intralymphatic immunization enhances DNA vaccination","volume":"98","author":"Maloy","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"22","key":"10.1016\/j.jconrel.2013.03.010_bb1430","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","article-title":"Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity","volume":"70","author":"Kreiter","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2013.03.010_bb1435","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1073\/pnas.0910609107","article-title":"Mature dendritic cells use endocytic receptors to capture and present antigens","volume":"107","author":"Platt","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.jconrel.2013.03.010_bb1440","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2003-02-0513","article-title":"Most lymphoid organ dendritic cell types are phenotypically and functionally immature","volume":"102","author":"Wilson","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jconrel.2013.03.010_bb1445","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.smim.2005.05.015","article-title":"Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm","volume":"17","author":"Villadangos","year":"2005","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2013.03.010_bb1450","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cncr.11462","article-title":"Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma","volume":"98","author":"Tagawa","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2013.03.010_bb1455","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/17435889.2.2.143","article-title":"Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals","volume":"2","author":"Gaspar","year":"2007","journal-title":"Nanomedicine (Lond.)"},{"issue":"13","key":"10.1016\/j.jconrel.2013.03.010_bb1585","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","article-title":"Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics","volume":"61","author":"Gaspar","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.03.010_bb1590","series-title":"International Handbook on Regulating Nanotechnologies","first-page":"291","article-title":"Chapter 14: therapeutic products: regulating drugs and medical devices","author":"Bowman","year":"2010"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1595","author":"European Medicines Agency C"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1600","series-title":"EMEA\/CHMP\/VWP\/164653\/2005","article-title":"Note for guidance on the clinical evaluation of vaccines [Internet]","author":"European Medicines Agency C","year":"2005"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1605","series-title":"EMEA\/CHMP\/VEG\/134716\/2004","article-title":"Guideline on adjuvants in vaccines for human use [Internet]","author":"European Medicines Agency C","year":"2005"},{"key":"10.1016\/j.jconrel.2013.03.010_bb1485","unstructured":"Food and Drugs Administration O of C, Tissue and Gene Therapies. CLINICAL CONSIDERATIONS FOR THERAPEUTIC CANCER VACCINES [Internet]. FDA's Center for Biologics Evaluation and Research, 2011. (http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/vaccines\/ucm278673.pdf)."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:27:44Z","timestamp":1759159664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365913001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":297,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0168365913001533"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.03.010","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune system targeting by biodegradable nanoparticles for cancer vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}